Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Objective. The present study was conducted to compare the efficacy of metformin combined with diammonium glycyrrhizinate enteric-coated capsule (DGEC) versus metformin alone versus DGEC alone for the treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2D...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2017-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2017/8491742 |
| id |
doaj-3cdb172d7e4d492b9bf7f4bb736186c6 |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Rong Zhang Keran Cheng Shizan Xu Sainan Li Yuqing Zhou Shunfeng Zhou Rui Kong Linqiang Li Jingjing Li Jiao Feng Liwei Wu Tong Liu Yujing Xia Jie Lu Chuanyong Guo Yingqun Zhou |
| spellingShingle |
Rong Zhang Keran Cheng Shizan Xu Sainan Li Yuqing Zhou Shunfeng Zhou Rui Kong Linqiang Li Jingjing Li Jiao Feng Liwei Wu Tong Liu Yujing Xia Jie Lu Chuanyong Guo Yingqun Zhou Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus Gastroenterology Research and Practice |
| author_facet |
Rong Zhang Keran Cheng Shizan Xu Sainan Li Yuqing Zhou Shunfeng Zhou Rui Kong Linqiang Li Jingjing Li Jiao Feng Liwei Wu Tong Liu Yujing Xia Jie Lu Chuanyong Guo Yingqun Zhou |
| author_sort |
Rong Zhang |
| title |
Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus |
| title_short |
Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus |
| title_full |
Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus |
| title_fullStr |
Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus |
| title_full_unstemmed |
Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus |
| title_sort |
metformin and diammonium glycyrrhizinate enteric-coated capsule versus metformin alone versus diammonium glycyrrhizinate enteric-coated capsule alone in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus |
| publisher |
Hindawi Limited |
| series |
Gastroenterology Research and Practice |
| issn |
1687-6121 1687-630X |
| publishDate |
2017-01-01 |
| description |
Objective. The present study was conducted to compare the efficacy of metformin combined with diammonium glycyrrhizinate enteric-coated capsule (DGEC) versus metformin alone versus DGEC alone for the treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). Subjects and Methods. 163 patients with NAFLD and T2DM were enrolled in this 24-week study and were randomized to one of three groups: group 1 was treated with metformin alone; group 2 was treated with DGEC alone; group 3 received metformin plus DGEC combination therapy. Anthropometric parameters, liver function, lipid profile, serum ferritin (SF), metabolic parameters, liver/spleen computed tomography (CT) ratio, and fibroscan value were evaluated at baseline and after 8, 16, and 24 weeks of treatment. Results. After 24 weeks, significant improvements in all measured parameters were observed in three groups (P<0.05) except for the improvements in low density lipoprotein cholesterol (LDL-C) and metabolic parameters in group 2 which did not reach statistical significance (P>0.05). Compared with group 1 and group 2, the patients in group 3 had greater reductions in observed parameters apart from CB and TB (P<0.05). Conclusions. This study showed that metformin plus DGEC was more effective than metformin alone or DGEC alone in reducing liver enzymes, lipid levels, and metabolic parameters and ameliorating the degree of hepatic fibrosis in patients with NAFLD and T2DM. |
| url |
http://dx.doi.org/10.1155/2017/8491742 |
| work_keys_str_mv |
AT rongzhang metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT kerancheng metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT shizanxu metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT sainanli metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT yuqingzhou metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT shunfengzhou metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT ruikong metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT linqiangli metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT jingjingli metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT jiaofeng metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT liweiwu metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT tongliu metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT yujingxia metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT jielu metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT chuanyongguo metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus AT yingqunzhou metforminanddiammoniumglycyrrhizinateentericcoatedcapsuleversusmetforminaloneversusdiammoniumglycyrrhizinateentericcoatedcapsulealoneinpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitus |
| _version_ |
1725468502437920768 |
| spelling |
doaj-3cdb172d7e4d492b9bf7f4bb736186c62020-11-24T23:53:49ZengHindawi LimitedGastroenterology Research and Practice1687-61211687-630X2017-01-01201710.1155/2017/84917428491742Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes MellitusRong Zhang0Keran Cheng1Shizan Xu2Sainan Li3Yuqing Zhou4Shunfeng Zhou5Rui Kong6Linqiang Li7Jingjing Li8Jiao Feng9Liwei Wu10Tong Liu11Yujing Xia12Jie Lu13Chuanyong Guo14Yingqun Zhou15Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai 200072, ChinaObjective. The present study was conducted to compare the efficacy of metformin combined with diammonium glycyrrhizinate enteric-coated capsule (DGEC) versus metformin alone versus DGEC alone for the treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). Subjects and Methods. 163 patients with NAFLD and T2DM were enrolled in this 24-week study and were randomized to one of three groups: group 1 was treated with metformin alone; group 2 was treated with DGEC alone; group 3 received metformin plus DGEC combination therapy. Anthropometric parameters, liver function, lipid profile, serum ferritin (SF), metabolic parameters, liver/spleen computed tomography (CT) ratio, and fibroscan value were evaluated at baseline and after 8, 16, and 24 weeks of treatment. Results. After 24 weeks, significant improvements in all measured parameters were observed in three groups (P<0.05) except for the improvements in low density lipoprotein cholesterol (LDL-C) and metabolic parameters in group 2 which did not reach statistical significance (P>0.05). Compared with group 1 and group 2, the patients in group 3 had greater reductions in observed parameters apart from CB and TB (P<0.05). Conclusions. This study showed that metformin plus DGEC was more effective than metformin alone or DGEC alone in reducing liver enzymes, lipid levels, and metabolic parameters and ameliorating the degree of hepatic fibrosis in patients with NAFLD and T2DM.http://dx.doi.org/10.1155/2017/8491742 |